STOCK TITAN

Rapid Micro Biosystems (RPID) Stock News, Mar-Sep 2023

RPID NASDAQ

Rapid Micro Biosystems, Inc. reports news about its life sciences automation business for microbial quality-control testing in healthcare manufacturing. The company develops and sells the Growth Direct platform, proprietary consumables, LIMS connectivity, software and services used to automate microbial analysis for pharmaceuticals, medical devices and personal care products.

Recurring updates include financial results and guidance, Growth Direct system placements and validations, customer orders from global biopharma and CDMO manufacturers, and company participation in healthcare investor conferences. News also covers equity compensation actions and Nasdaq-related employment inducement grants tied to its public-company governance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
management
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
management
-
Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) is set to release its first quarter 2023 financial results on May 5, 2023, before market opening. The release will be accompanied by a webcast conference call at 8:30 AM EST, which will be accessible for replay for one year. The company specializes in automation solutions that enhance the manufacturing processes for healthcare products, including vaccines and biologics. Their Growth Direct System modernizes microbial quality control testing for pharmaceutical manufacturers, aiming to improve efficiency and compliance. Headquartered in Lowell, Massachusetts, Rapid Micro also has global operations in Europe.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) reported fourth quarter 2022 commercial revenue of $4.4 million, down from $5.2 million in Q4 2021. For full year 2022, total revenue was $17.1 million, a decline from $23.2 million in 2021. However, the recurring commercial revenue reached $11.0 million, a significant growth of 40%. The company forecasted 2023 revenue of at least $22.0 million, reflecting an approximate 30% increase. Notably, they maintained $138.4 million in cash with no debt. The net loss for Q4 2022 was $16.4 million, worsening from $14.6 million in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.98%
Tags

FAQ

What is the current stock price of Rapid Micro Biosystems (RPID)?

Rapid Micro Biosystems (RPID) last closed at $0.7350.

What is the market cap of Rapid Micro Biosystems (RPID)?

The market cap of Rapid Micro Biosystems (RPID) is approximately $37.4M.